{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["81(5)"],"submitter":["Jouvenot G"],"pubmed_abstract":["<h4>Importance</h4>A recent randomized clinical trial concluded that discontinuing medium-efficacy therapy might be a reasonable option for older patients with nonactive multiple sclerosis (MS), but there is a lack of data on discontinuing high-efficacy therapy (HET). In younger patients, the discontinuation of natalizumab and fingolimod is associated with a risk of rebound of disease activity.<h4>Objective</h4>To determine whether discontinuing HET in patients 50 years and older with nonactive MS is associated with an increased risk of relapse compared with continuing HET.<h4>Design, setting, and participants</h4>This observational cohort study used data from 38 referral centers from the French MS registry (Observatoire Français de la Sclérose en Plaques [OFSEP] database). Among 84704 pat"],"journal":["JAMA neurology"],"pagination":["490-498"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10964164"],"repository":["biostudies-literature"],"pubmed_title":["High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS."],"pmcid":["PMC10964164"],"pubmed_authors":["Collongues N","Le Page E","Labauge P","Kerbrat A","Heinzlef O","Giannesini C","Debouverie M","Pachot A","Rollot F","Moreau T","Kremer L","Casez O","Bakchine S","Vukusic S","Hankiewicz K","Cotton F","Maurousset A","Zephir H","Ciron J","Thouvenot E","Lefort M","Papeix C","Cabre P","Moulin S","Maillart E","Wiertlewsky S","Berger E","Guillememin F","Jouvenot G","OFSEP Investigators","Douek P","Audoin B","Pelletier J","Camdessanche JP","Clavelou P","Michel L","Maubeuge N","Defer G","Neau JP","Doghri I","Pottier C","Edan G","Magy L","Stankoff B","Montcuquet A","de Seze J","Labeyrie C","Bigaut K","Lubetzki C","Rigaud-Bully C","Casey R","Mathey G","Bourre B","Nifle C","Cohen M","Lebrun-Frenay C","Wahab A","Fromont A","Gout O","Ben-Nasr H","Al-Khedr A","Marignier R","Courbon G","Laplaud DA","Ruet A","Olaiz J"],"additional_accession":[]},"is_claimable":false,"name":"High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS.","description":"<h4>Importance</h4>A recent randomized clinical trial concluded that discontinuing medium-efficacy therapy might be a reasonable option for older patients with nonactive multiple sclerosis (MS), but there is a lack of data on discontinuing high-efficacy therapy (HET). In younger patients, the discontinuation of natalizumab and fingolimod is associated with a risk of rebound of disease activity.<h4>Objective</h4>To determine whether discontinuing HET in patients 50 years and older with nonactive MS is associated with an increased risk of relapse compared with continuing HET.<h4>Design, setting, and participants</h4>This observational cohort study used data from 38 referral centers from the French MS registry (Observatoire Français de la Sclérose en Plaques [OFSEP] database). Among 84704 pat","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 May","modification":"2025-06-25T03:04:32.279Z","creation":"2025-06-25T03:04:32.279Z"},"accession":"S-EPMC10964164","cross_references":{"pubmed":["38526462"],"doi":["10.1001/jamaneurol.2024.0395"]}}